Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feriel Azibani

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Mabs|May 21, 2026
Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3Magali Genest, Dirk Van Lier, Theo Ikenna Uba, et al.
Plos One|June 6, 2012
Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive miceFeriel Azibani, Yvan Devaux, Guillaume Coutance, et al.
International Journal of Cardiology|August 9, 2018
Reducing late maternal death due to cardiovascular disease - A pragmatic pilot studyKaren Sliwa, Feriel Azibani, Johann Baard, et al.
Experimental Hematology & Oncology|April 19, 2025
Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancersTai Van Nguyen, Eurydice Angeli, Diaddin Hamdan, et al.
Mabs|May 21, 2026
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primatesDirk van Lier, Magali Genest, Adrien Picod, et al.
Plos One|August 28, 2020
Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept studyBenjamin Deniau, Alice Blet, Karine Santos, et al.
ESC Heart Failure|March 16, 2026
Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF StudyJolie Bruno, Aziz Daghmouri, Malha Sadoune, et al.
European Journal of Heart Failure|September 1, 2019
Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamicsBenjamin Deniau, Linda Rehfeld, Karine Santos, et al.
ESC Heart Failure|February 18, 2020
Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markersFeriel Azibani, Tobias J Pfeffer, Melanie Ricke-Hoch, et al.
Experimental Hematology & Oncology|April 15, 2024
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastasesEurydice Angeli, Justine Paris, Olivier Le Tilly, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Mabs|May 21, 2026
Development and non-clinical characterization of Procizumab (invobenitug): a humanized antibody neutralizing circulating DPP3Magali Genest, Dirk Van Lier, Theo Ikenna Uba, et al.
Plos One|June 6, 2012
Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive miceFeriel Azibani, Yvan Devaux, Guillaume Coutance, et al.
International Journal of Cardiology|August 9, 2018
Reducing late maternal death due to cardiovascular disease - A pragmatic pilot studyKaren Sliwa, Feriel Azibani, Johann Baard, et al.
Experimental Hematology & Oncology|April 19, 2025
Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancersTai Van Nguyen, Eurydice Angeli, Diaddin Hamdan, et al.
Mabs|May 21, 2026
Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primatesDirk van Lier, Magali Genest, Adrien Picod, et al.
Plos One|August 28, 2020
Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept studyBenjamin Deniau, Alice Blet, Karine Santos, et al.
ESC Heart Failure|March 16, 2026
Cardiac Biomarkers Response Under Angiotensin Receptor-Neprilysin Inhibitor: A Sub-Analysis of the Natrium-HF StudyJolie Bruno, Aziz Daghmouri, Malha Sadoune, et al.
European Journal of Heart Failure|September 1, 2019
Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamicsBenjamin Deniau, Linda Rehfeld, Karine Santos, et al.
ESC Heart Failure|February 18, 2020
Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markersFeriel Azibani, Tobias J Pfeffer, Melanie Ricke-Hoch, et al.
Experimental Hematology & Oncology|April 15, 2024
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastasesEurydice Angeli, Justine Paris, Olivier Le Tilly, et al.
Pageof 6